Mankind Pharma broadens its PetStar offerings with the introduction of PetStar Delight, a new line of cat food products.
Mankind Pharma, a leading pharmaceutical company, has expanded its PetStar brand into the cat food segment with the launch of PetStar Delight. This new range of cat food is designed to support overall feline wellness and marks a significant milestone in the company’s pet care journey, which began with the launch of PetStar dog food in 2022. PetStar Delight is formulated with a powerful blend of functional ingredients, including cranberry, turmeric, and taurine, which provide various health benefits such as urinary health, immunity, and digestive health.
The product is manufactured in Thailand and adheres to stringent quality standards, offering pet parents a clean label option with no artificial colors or preservatives. The PetStar Delight range is available in three flavors – salmon, tuna, and ocean fish – and caters to two distinct life stages: kitten (one to 12 months) and adult (12 months and above). Each life stage has a specific nutritional profile, with the kitten range containing 32% protein and 12% fat, and the adult range containing 30% protein and 10% fat.
According to Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, the company has witnessed the tremendous potential of India’s pet care market and the evolving needs of pet parents since launching PetStar in 2022. With PetStar Delight, the company aims to bring the same commitment to quality, affordability, and wellness that defines its pharmaceutical business and dog food range into feline nutrition. Dr. Piyush Prashant, Vice President and Head of Pet Food Division, Mankind Pharma, added that the company has applied the same commitment to quality for cats as it did for dogs, with each recipe combining superior palatability with functional nutrition.
The PetStar Delight range incorporates ingredients with specific health benefits, such as prebiotic beta-glucans and MOS for gut health, natural fiber for hairball control, and salmon oil for brain development. The company has created a comprehensive solution that addresses the real health concerns of cat owners, making it a significant addition to the pet care market. With the launch of PetStar Delight, Mankind Pharma aims to provide scientifically formulated nutrition that supports the complete health of pets across species and life stages.
The Future of Mexican Healthcare: Harnessing Data and Differentiation
Glenmark Pharmaceuticals has significantly expanded its presence in the “High Latin America” region, which includes Mexico, Colombia, Ecuador, Peru, Central America, and the Caribbean, over the past four years. The company’s growth in this region has been driven by innovation, product launches, and operational efficiency. In Mexico, Glenmark has nearly tripled its revenue, doubled its workforce, and expanded its sales force in recent years. The company attributes its success to its strategic use of data analytics, which enables it to identify high-growth therapeutic niches and make informed investment decisions.
Glenmark is also leveraging digitalization and telemedicine to accelerate research and adoption of new therapies. The company has a strong portfolio in respiratory care, dermatology, and oncology, and is focusing on launching innovative products in these areas. In Mexico, Glenmark is a market leader in oral solids and nasal sprays for allergic rhinitis, and has recently launched a new product that reached the number three position in nasal spray combinations within 10 months.
The company’s growth strategy also involves forming strategic alliances and co-development projects. Glenmark has established partnerships with local and regional laboratories to commercialize its molecules, and has also entered into collaborations with major pharmaceutical companies such as AstraZeneca. These partnerships allow Glenmark to expand its therapeutic coverage and maintain a robust pipeline of new products.
Over the next three to five years, Glenmark plans to launch a range of new products in respiratory, dermatology, and oncology. The company is committed to continuing to innovate and launch differentiated products that provide physicians with expanded therapeutic options and improve patient outcomes. In terms of digitalization, Mexico is seen as a strategic hub with enormous potential, offering greater business certainty and scalability than other Latin American countries.
Regulatory trends in Latin America are also influencing access to specialized therapies, with agencies increasingly adopting accelerated approval pathways and recognizing approvals from high-surveillance markets. Glenmark is preparing for these trends by digitalizing its processes and improving its regulatory capabilities. The company’s advice to other pharmaceutical companies operating in Mexico is to identify market niches, continuous innovation, and align investment decisions with long-term objectives. Overall, Glenmark’s position in Latin America is strong, and the company is well-placed to continue growing and expanding its presence in the region.
Vitabiotics, owned by the Lalvani family, is reportedly in talks for a Rs 11,800 crore buyout, with the Lupin Eyes deal putting the brand under scrutiny.
The pharmaceutical company, Lupin, is reportedly in discussions to acquire Vitabiotics, a UK-based vitamins and supplements manufacturer, in a deal estimated to be worth £1 billion (approximately Rs 11,800 crore). Vitabiotics is a family-owned brand, founded by the Lalvani family, and is known for its popular brands such as Pregnacare, Osteocare, and Wellman.
The potential acquisition is seen as a strategic move by Lupin to expand its presence in the global vitamins and supplements market. Vitabiotics has a strong presence in the UK and other European countries, and its products are also sold in several other markets, including Asia and the Americas. The company has a reputation for producing high-quality products and has a strong distribution network.
If the deal goes through, it would be one of the largest acquisitions by an Indian pharmaceutical company in recent years. Lupin has been looking to expand its portfolio and presence in the global market, and the acquisition of Vitabiotics would help the company to achieve this goal.
The Lalvani family, which owns Vitabiotics, has been considering options for the future of the company, including a potential sale. The family has built the company into a successful and respected brand over several decades, and the sale would likely be a significant exit for the family.
The acquisition would also provide Lupin with access to new markets and distribution channels, as well as a portfolio of well-known and respected brands. Vitabiotics has a strong research and development capability, which would also be a valuable asset for Lupin.
Overall, the potential acquisition of Vitabiotics by Lupin is a significant development in the pharmaceutical industry, and would be a major milestone for both companies. The deal would require regulatory approvals and would be subject to due diligence and other conditions, but if it goes through, it would be a major expansion of Lupin’s presence in the global market.
Apollo Hospitals Bolsters Organ Transplant Capabilities with Specialized Heart and Lung Transplant Unit
Apollo Hospitals has launched a dedicated Heart & Lung Transplantation and Mechanical Circulatory Support (MCS) Unit at its Seshadripuram facility in Bengaluru, Karnataka. This marks a significant milestone in the state’s transplant landscape, enhancing access to complex cardiothoracic care for patients across Karnataka and neighboring regions. The new unit is equipped with state-of-the-art facilities, including transplant-ready ICUs, specialized OTs, advanced monitoring systems, ECMO and MCS support, and dedicated rehabilitation pathways.
The launch was attended by Dr. J Ravishankar IAS, Managing Director of Bengaluru Metro Rail Corporation Ltd (BMRCL), who highlighted the importance of urban mobility in supporting time-sensitive emergency care. He noted that Namma Metro played a vital role in the timely transport of a donor heart, demonstrating how public infrastructure can directly support life-saving healthcare.
The new unit will offer patients a range of advanced therapies, including heart, lung, and combined heart-lung transplantation, as well as temporary and durable mechanical circulatory support. The programme is clinically integrated and multidisciplinary, with a team of experts working together to deliver seamless care for end-stage heart and lung disease.
Dr. Kumud Kumar Dhital, Programme and Surgical Director, noted that the team has built a robust transplant service over the past two years and is now poised to deliver consistently safe and successful outcomes. Dr. Srinivas Rajagopala, Lead Lung Failure and Transplant Pulmonologist, emphasized the importance of continuity in lung care, highlighting the need for meticulous pre- and post-transplant care.
The launch event also featured patient stories, with recipients of Apollo’s transplant services sharing emotional testimonies and thanking donor families and medical teams for giving them a second chance at life. One patient, who received a heart transplant thanks to the timely transport of a donor heart via Namma Metro, praised the “right infrastructure and the right medical expertise” that came together to save his life.
The new unit is expected to significantly enhance Karnataka’s transplant capabilities, meeting the rising demand for advanced cardiac and respiratory interventions. With Karnataka emerging as one of India’s most active contributors to the organ donation pool, the Apollo programme aims to make a meaningful impact in the lives of patients and families across the region.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.